Investor Relations
Investor Relations Contact:
Anne Marie Fields
Bruce Voss

Media Contact
Rooney & Associates
Terry Rooney
Marion Janic

OPKO Health to Present at the Jefferies Autumn 2015 Global Healthcare Conference more »

OPKO Licensee TESARO Announces the Launch of VARUBI(TM) (Rolapitant) in the United States more »

OPKO 4Kscore Test Receives Category I CPT Code Approval more »

OPKO Announces Third Quarter Financial and Operating Results more »

Investor Relations

OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets.  Our diagnostics business includes Bio-Reference Laboratories, the nation’s third-largest clinical laboratory with a core genetic testing business and a 420-person salesforce to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros®1 in-office immunoassay platform.  Our pharmaceutical business features Rayaldee™, a treatment for secondary hyperparathyroidism in stage 3-4 chronic kidney disease patients with vitamin D deficiency (March 29, 2016 PDUFA date) and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation approved by FDA and pending launch by partner Tesaro, IV formulation in Phase 3).  Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia (entering Phase 2a).  We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy.

Former shareholders of Bio-Reference Laboratories, Inc. that have questions related to the exchange of BRLI shares to OPK shares, please contact our exchange agent, American Stock Transfer & Trust Company, LLC, toll free at (877) 248-6417 or (718) 921-8317.

  • Stock Information

Ticker OPK Exchange NYSE
Last Price 10.94 Change 0.04 down
Open 11.01 Previous Close 10.98
Day High 11.20 Day Low 10.83
52-Week High 19.20 52-Week Low 8.16
Quotes delayed at least 20 minutes. Information provided by eSignal.

Email  Sign up for email alerts